Crescent Biopharma Extends Cash Runway to H2 2028 with Q2 2026 Results, Maps Out Multiple 2027 Data Catalysts
CBIO sits 69% above its 52-week low of $8.72.
Summary
Crescent Biopharma posted a $24.8M net loss for Q2 2026 and reported $305.1M in pro forma cash, funding operations into H2 2028. A series of clinical data readouts across its bispecific antibody and ADC pipeline begins in Q1 2027.
Key Events · Earnings and Guidance · CBIO
-
Q2 2026 Financial Results
The quarter delivered a net loss of $24.8 million ($0.74/share), driven by R&D spend of $19.4 million and G&A of $8.7 million. Cash and equivalents stood at $171.6 million as of June 30, 2026.
-
Cash Runway Extended to H2 2028
Pro forma cash of $305.1 million, which includes $133.5 million in net proceeds from the July 2026 public offering, is expected to fund operations into the second half of 2028 — beyond key clinical catalysts.
-
CR-001 Data Readouts in 2027
Proof-of-concept data from the ASCEND Phase 1/2 trial is expected in Q1 2027, with initial combination data alongside chemotherapy and sac-TMT (via the Kelun-Biotech collaboration) anticipated by mid-2027.
-
ADC Pipeline Advancing
An IND filing for CR-002 (PD-L1 ADC) is planned for mid-2026, with a Phase 1/2 start in H2 2026 and data in H2 2027. Meanwhile, the Phase 1/2 trial for CR-003 (ITGB6 ADC) is ongoing in China, with data expected in Q1 2027.
Analysis · CBIO · Life Sciences
Second-quarter 2026 financials from Crescent Biopharma showed a net loss of $24.8 million alongside R&D spending of $19.4 million, reflecting a ramp-up in clinical activity. Bolstered by the recent $143.7 million offering, pro forma cash of $305.1 million pushes the runway into the second half of 2028 — comfortably past key data readouts. The catalyst calendar is dense: proof-of-concept data for lead asset CR-001 arrives in Q1 2027, combination data with chemotherapy and with sac-TMT follow by mid-2027, and initial results for ADC programs CR-002 and CR-003 are slated for H2 2027 and Q1 2027, respectively. With the cash position and timeline now clear, near-term financing risk recedes and multiple value-inflection points line up over the next 12–18 months.
At the time of this filing, CBIO was trading at $14.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $545.9M. The 52-week trading range was $8.72 to $27.41. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.